» Articles » PMID: 36909245

Role of the Renin-angiotensin System in the Pathophysiology of Coronary Heart Disease and Heart Failure: Diagnostic Biomarkers and Therapy with Drugs and Natural Products

Overview
Journal Front Physiol
Date 2023 Mar 13
PMID 36909245
Authors
Affiliations
Soon will be listed here.
Abstract

The renin-angiotensin system (RAS) plays a pivotal role in blood pressure regulation. In some cases, this steering mechanism is affected by various deleterious factors (mainly the overactivation of the RAS) causing cardiovascular damage, including coronary heart disease (CHD) that can ultimately lead to chronic heart failure (CHF). This not only causes cardiovascular disability and absenteeism from work but also imposes significant healthcare costs globally. The incidence of cardiovascular diseases has escalated exponentially over the years with the major outcome in the form of CHD, stroke, and CHF. The involvement of the RAS in various diseases has been extensively researched with significant limelight on CHD. The RAS may trigger a cascade of events that lead to atherosclerotic mayhem, which causes CHD and related aggravation by damaging the endothelial lining of blood vessels various inflammatory and oxidative stress pathways. Although there are various diagnostic tests and treatments available in the market, there is a constant need for the development of procedures and therapeutic strategies that increase patient compliance and reduce the associated side effects. This review highlights the advances in the diagnostic and treatment domains for CHD, which would help in subjugating the side effects caused by conventional therapy.

Citing Articles

Impact of renin-angiotensin system targeted therapy on aortic elastic properties assessed by computed tomography.

Mileva N, Panayotov P, Hristova I, Koleva G, Georgieva D, Ivanova R Int J Cardiol Heart Vasc. 2024; 55:101562.

PMID: 39649025 PMC: 11625146. DOI: 10.1016/j.ijcha.2024.101562.


Downregulation of neuronal nitric oxide synthase (nNOS) within the paraventricular nucleus in Ins2-type-1 diabetic mice contributes to sympatho-excitation.

Patel T, Gao L, Boomer S, Liu X, Patel K, Zheng H Nitric Oxide. 2024; 154():1-7.

PMID: 39521242 PMC: 11729414. DOI: 10.1016/j.niox.2024.11.001.


Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications-A Narrative Review.

Todor S, Ichim C, Boicean A, Mihaila R Curr Issues Mol Biol. 2024; 46(8):8407-8423.

PMID: 39194713 PMC: 11353264. DOI: 10.3390/cimb46080496.


Association of rs5051 and rs699 polymorphisms in angiotensinogen with coronary artery disease in Iranian population: A case-control study.

Mirahmadi M, Salehi A, Golalipour M, Bakhshandeh A, Shahbazi M Medicine (Baltimore). 2024; 103(11):e37045.

PMID: 38489704 PMC: 10939567. DOI: 10.1097/MD.0000000000037045.


Interplay of Angiotensin Peptides, Vasopressin, and Insulin in the Heart: Experimental and Clinical Evidence of Altered Interactions in Obesity and Diabetes Mellitus.

Szczepanska-Sadowska E Int J Mol Sci. 2024; 25(2).

PMID: 38279313 PMC: 10816525. DOI: 10.3390/ijms25021310.


References
1.
McIlvennan C, Allen L . Palliative care in patients with heart failure. BMJ. 2016; 353:i1010. DOI: 10.1136/bmj.i1010. View

2.
Economou E, Oikonomou E, Siasos G, Papageorgiou N, Tsalamandris S, Mourouzis K . The role of microRNAs in coronary artery disease: From pathophysiology to diagnosis and treatment. Atherosclerosis. 2015; 241(2):624-33. DOI: 10.1016/j.atherosclerosis.2015.06.037. View

3.
Han Y, Wang M, Shen J, Zhang Z, Zhao M, Huang J . Differential efficacy of methylcobalamin and alpha-lipoic acid treatment on symptoms of diabetic peripheral neuropathy. Minerva Endocrinol. 2016; 43(1):11-18. DOI: 10.23736/S0391-1977.16.02505-0. View

4.
Sobenin I, Myasoedova V, Iltchuk M, Zhang D, Orekhov A . Therapeutic effects of garlic in cardiovascular atherosclerotic disease. Chin J Nat Med. 2019; 17(10):721-728. DOI: 10.1016/S1875-5364(19)30088-3. View

5.
Arnett D, Blumenthal R, Albert M, Buroker A, Goldberger Z, Hahn E . 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140(11):e563-e595. PMC: 8351755. DOI: 10.1161/CIR.0000000000000677. View